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Mitochondrial DNA (mtDNA) content in ovarian carcinomas was assessed by quantitative PCR. Results show that mtDNA content
in tumour cell was significantly higher than that in normal ovary. Change in mtDNA content was not related with patients’ age or
tumour stages. However, the average mtDNA copy number in pathological low-grade tumours was over two-fold higher than that in
high-grade carcinomas (P¼0.012). Moreover, type I carcinomas also had a significantly higher mtDNA copy number than in type II
carcinomas (P¼0.019). Change in mtDNA content might be an important genetic event in the progression of ovarian carcinomas.
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Mitochondrion has its own genome, the mitochondrial DNA
(mtDNA). Unlike nuclear genome, mtDNA exists in each cell with
several hundreds to more than 10000 copies. Generally, mtDNA
content is tissue-specific and has a steady-state level in each type
of tissue. Its maintenance depends mainly on nuclear-encoded
factors which usually confers function through the Tfam pathway
(Moraes, 2001). Mitochondrial DNA copy number in cell is not
under stringent control; and various internal or external factors
associated with ATP demand may influence its level, such as:
exercise (Lim et al, 2000), hypoxia (Hoppeler et al, 2003), and
steroid hormones stimulation (Weitzel et al, 2003). It is well
known that carcinoma cells proliferate fast and survive in strict
microenvironment, for example, under hypoxic condition. Either
down- or upregulation of mtDNA content has been observed in a
number of human malignancies (Jones et al, 2001; Simonnet et al,
2002; Lee et al, 2004; Wong et al, 2004). More importantly, mtDNA
content change has also been found to be associated with
histological types of gastric carcinoma (Wu et al, 2005).
In our previous studies, we have demonstrated the occurrence of
high frequencies of somatic mtDNA mutations in endometrial (Liu
et al, 2003) and ovarian carcinomas (Liu et al, 2001). In addition,
we have also found that mtDNA copy number was significantly
elevated in endometrial adenocarcinoma when compared with
normal endometrial glandular epithelium (Wang et al, 2005). To
further determine the mtDNA content change and its relationship
with cancer, we therefore investigate the mtDNA copy number in
primary ovarian carcinomas.
MATERIALS AND METHODS
Frozen samples of 38 cases of primary epithelial ovarian
carcinomas and four borderline ovarian tumours diagnosed and
treated from January 1991 to December 2004 were retrieved
without specific selection for this study. The mean age is 52
(ranging from 26 to 83). The clinical and pathologic characteristics
of the 42 patients with ovarian carcinomas are shown in Table 1. In
addition, frozen samples of 17 normal ovarian tissues were also
used for this study. Use of clinical samples in this study was
approved by the Ethics Committee of the University of Hong Kong.
In order to obtain pure tumour cell from cancerous tissues, laser
capture microdissection (LCM) was employed. The LCM proce-
dure and DNA isolation from LCM procured samples were
previously described in detail (Wang et al, 2005). The recipes
and conditions of quantitative PCR reaction were also described in
our previous study (Wang et al, 2005).
The raw data were processed using the software accompanying
the ABI PRISM 7700 Sequencing Detection System. Linear
regression was used to analyse the response of Ct (the cycle
number at which fluorescence raises above the baseline level
during real-time quantitative PCR) vs the logarithm of the DNA
concentration. Pearson’s correlation was used to test the relation-
ship between patients’ age and mtDNA copy numbers in tumour
tissues. The copy number comparison between groups was
performed by nonparametric test (Mann–Whitney or Kruskal–
Wallis test). Statistical significance was set at Po0.05.
RESULTS
Table 1 shows the mtDNA copy number per cell of the 42 ovarian
cancer samples and the 17 normal ovarian tissues. Mitochondrial
DNA content is significantly higher in ovarian tumours than in
normal ovarian tissues (Po0.001) (Figure 1A). The mtDNA copy
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sTable 1 MtDNA copy number and clinicopathological characteristics of patients
Tissue Code Age Diagnosis
a Stage
b Grade
c Type
d MtDNA copy number
Tumour OV100 49 Mucinous I Borderline I 983
OV086 68 Mucinous I Borderline I 4913
G119 75 Mucinous III Borderline I 10516
G104 58 Clear cell I Borderline I 4943
G147 31 Serous I G1 I 1337
G007 64 Serous II G1 I 16772
OV016 63 Mucinous I G1 I 8220
OV078 42 Endometrioid II G1 I 936
G087 39 Serous I G2 I 3539
G215 55 Serous III G2 I 9702
G213 38 Serous IV G2 I 6486
OV006 26 Mucinous I G2 I 9845
OV070 44 Endometrioid II G2 I 1976
G209 58 Adenocarcinoma II G2 I 2103
G164 64 Serous I G3 II 2252
OV014 48 Serous I G3 II 462
OV092 45 Serous II G3 II 707
G020 57 Serous III G3 II 1995
G117 51 Serous III G3 II 1064
G208 39 Serous III G3 II 7104
G212 45 Serous III G3 II 1839
OV034 40 Serous III G3 II 4298
OV074 68 Serous III G3 II 2925
G110 62 Serous IV G3 II 6771
G114 43 Serous IV G3 II 948
OV008 48 Serous IV G3 II 794
OV120 35 Serous IV G3 II 3735
G120 68 Serous III 1554
OV004 39 Mucinous IV G3 I 519
OV064 46 Endometrioid I G3 II 1516
OV022 71 Endometrioid II G3 II 1659
G040 72 Endometrioid III G3 II 1132
OV002 36 Endometrioid III 3816
OV042 44 Adenocarcinoma III G3 II 4214
G014 83 Adenocarcinoma III G3 II 2565
G216 59 Clear cell I G3 I 3554
OV032 37 Clear cell I G3 I 3611
OV076 63 Clear cell II G3 I 2591
OV012 54 Clear cell III G3 I 2415
OV098 44 Poorly differentiated III G3 II 1770
OV108 47 Poorly differentiated II G3 II 493
OV110 48 Poorly differentiated III G3 II 444
Normal Nor ov01 1640
Nor ov02 771
Nor ov03 943
Nor ov04 856
Nor ov05 1156
Nor ov06 920
Nor ov07 913
Nor ov08 865
Nor ov09 737
Nor ov10 799
Nor ov11 532
Nor ov12 1367
Nor ov13 766
Nor ov14 809
Nor ov15 753
Nor ov16 705
Nor ov17 1254
Abbreviation: mtDNA¼mitochondrial DNA.
aThe histological types of tumour were classified according to WHO criteria.
bThe stage of each carcinoma was established
according to the International Federation of Gynaecology and Obstetrics (FIGO) criteria.
cThe grades of tumour were classified based on WHO criteria, Grades 1 (well
differentiated), 2 (moderately differentiated), and 3 (poorly differentiated). Two carcinoma patients were uninformative on the grading.
dThe types of tumour were classified
based on recent studies (Shih Ie and Kurman, 2004; Bell, 2005), Type I tumours composed of mucinous carcinomas, low-grade serous and endometrioid carcinomas, and clear
cell carcinomas. Type II tumours include high-grade serous and endometrioid carcinomas as well as undifferentiated carcinoma. Three adenocarcinomas were treated to be same
as serous and endometrioid carcinomas.
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ages.
The levels of mtDNA in normal ovary was higher than that in
endometrium (Wang et al, 2005) (P¼0.020) (Figure 1B). In
ovarian tumours, an average of 354873421 copies of mtDNA was
present in tumour cells. The highest and lowest copy numbers of
mtDNA in cell were 16772 and 444, respectively (Table 1).
Compared with endometrial carcinomas (average mtDNA copy
number¼201272317 copies) (Wang et al, 2005), a significantly
higher level of mtDNA copy number was found in ovarian
carcinomas (P¼0.001) (Figure 1C).
From the 42 patients, 20 were diagnosed as early-stage tumours,
stage I or stage II; whereas 22 patients suffered from advanced
carcinomas, stage III or stage IV. There is no significant difference
of mtDNA copy numbers between the early-stage tumours
(average at 362173974 copies per cell) and advanced stage
carcinomas (average at 348272923 copies per cell) (Figure 1D).
As two patients were uninformative on the grading, the analysis
was carried out in 40 patients. No significant difference was
observed between the four borderline tumours and other invasive
carcinomas (Mann–Whitney test, Z¼ 1.328, P¼0.199). In the 26
cases of Grade 3 carcinomas, the mean value of mtDNA content in
tumour cells was 236171799 copies. In the other 14 patients with
lower-grade tumours (including the four borderline tumours), the
mean copy of mtDNA molecules in each cell were 587774659
copies, it is over two-folds and significantly higher (P¼0.012) than
that in the higher-grade carcinomas (Figure 1E).
The mtDNA copy numbers among different histological
subtypes of carcinomas was not significantly different (Kruskal–
Wallis test, w
2¼8.397, P¼0.136, and df¼5). Nevertheless, the
mucinous tumours seem to have relatively higher level of mtDNA
content than other subtypes. In the 42 cases, except two subjects of
serous carcinoma uninformative on grading, 19 cases were
classified as type I tumours and the other 21 cases were classified
as type II tumour (for tumour classification, please see footnotes of
Table 1). An average of 499874279 copies of mtDNA was detected
in type I tumours; whereas, the mean copy number of mtDNA in
type II tumours is 231871930. It is remarkable lower than that in
the type I tumours (P¼0.019) (Figure 1F).
DISCUSSION
In this study, mtDNA content in ovarian carcinoma cells was
found significantly higher than that in normal ovary. Except for a
few reports, the change in mtDNA content does not associate with
clinicopathological characteristics. Interestingly, in present study,
we found that the mtDNA copy number in high-grade tumours is
significantly lower than that in low-grade tumour. As the grade of
tumour is a crucial prognostic factor, therefore, mtDNA content
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Figure 1 The comparisons of mtDNA copy number in cells among different groups of data. (A) The mean mtDNA copy number in normal ovarian cells
(n¼17) and ovarian carcinoma cells (n¼42) are 9297276 and 354873421 copies per cell, respectively. A significant difference was detected (Mann–
Whitney test, Z¼ 3.983, Po0.001). (B) The mtDNA copy number in normal ovarian cells was higher than that in normal endometrial cells (7687573,
n¼41) (Mann–Whitney test, Z¼ 2.332, P¼0.020). (C) The mean mtDNA copy number in ovarian carcinoma cells (354873421, n¼42) and
endometrial carcinoma cells (201372317, n¼65) were significantly different (Mann–Whitney test, Z¼ 3.311, P¼0.001). (D) No significant difference of
levels of mtDNA copy number between the early-stage tumour (362173974, n¼20) and advanced stage tumour (348272923, n¼22) was detected
(Mann–Whitney test, Z¼ 0.327, P¼0.743). (E) Significant difference of mtDNA copy number was observed between Grade 3 carcinomas
(236171799, n¼26) and the low-grade tumours (587774659, n¼14) (Mann–Whitney test, Z¼ 2.495, P¼0.012). (F) The mtDNA content in the
type I tumours (499874279, n¼19) was significantly higher than that in the type II tumours (231871930, n¼21) (Mann–Whitney test, Z¼ 2.343,
P¼0.019).
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ovarian carcinoma.
Mitochondrial DNA copy number change was also found related
with other human diseases. A significantly lower level of mtDNA
content was observed in oocytes from women with ovarian
insufficiency (May-Panloup et al, 2004). In addition, increased
sperm mtDNA content was observed in male infertility (May-
Panloup et al, 2003). The findings suggested that the change of
mtDNA copy number was related with the impairment of cellular
physiologic function. A probable explanation is that the change in
mtDNA content would likely cause or be caused by the deficiencies
in oxidative phosphorylation activity. Reactive oxygen species
generation in mitochondria, which lead to DNA oxidative damage
in cells, could thus impair cell function.
The significantly different levels of mtDNA content in different
grades of tumour may be accounted for either by the down-
regulation in mtDNA replication in the high-grade tumours, or
upregulation in mtDNA replication in low-grade tumours. Detec-
tion of many mtDNA alterations in the premalignant or
preinvasive lesions indicated that mtDNA alterations could be an
early genetic event in tumorigenesis (Chen et al, 2002; Ha et al,
2002; Durham et al, 2003). Mitochondrial DNA copy number was
suggested to be increased by a feedback mechanism that
compensates for the defective respiratory system owing to mutated
mtDNA (Lee et al, 2000). So, it is possible that mtDNA copy
number increased in early- and lower-grade malignancies.
On the other hand, long-term exposure to severe environmental
insult such as hypoxia decreases the mitochondrial content of
muscle fibres (Hoppeler et al, 2003). Undoubtedly, mitochondria
are oxygen sensitive and the mtDNA content decrease might
account for hypoxia. So, an alternative explanation of the decrease
of mtDNA copy number in high-grade tumour is due to the fact
that such tumour has rapid proliferation rate, and thus, survives in
more severe hypoxia microenvironment leading to the down-
regulation of the mtDNA replication.
The most important finding in this study is the association
between decreased mtDNA copy number with high grade and
histological subtype of ovarian carcinoma. The histopathological
phenotypes of ovarian carcinoma are complex. The epithelial-
derived tumours including serous, mucinous, endometrioid, clear
cell, transitional, squamous, mixed, and undifferentiated types
comprise the majority of malignant tumours. Each of these
histological subtypes is associated with distinct molecular genetic
alterations (Shih Ie and Kurman, 2004; Bell, 2005). Based on recent
clinicopathological and molecular studies, it has been proposed
that surface epithelial tumours could be divided into two broad
categories, type I and type II tumours. Mutations in KRAS and
BRAF have been found to be common in low-grade serous and
mucinous ovarian carcinomas (Gemignani et al, 2003; Sieben et al,
2004). KRAS belongs to RAS families which coding proto-oncogene
that functions as a relay switch that transduces various growth
signals in the cell surface to the nucleus through activation of the
RAS–RAF–MEK–ERK–MAP kinase signalling pathway. Till now,
no report connected the regulation of mtDNA replication with the
genetic alterations in RAS–RAF pathway. As shown above, type I
tumour had a significantly higher mtDNA copy number than that
in type II tumour. So, whether or not a potential relationship
between the genetic alterations in RAS–RAF pathway and mtDNA
content change would be an interesting field to be explored.
On the other hand, mutations in the tumour suppressor
molecule p53 were detected in type II tumours frequently (Shih
Ie and Kurman, 2004). Recent studies provided the potential
mechanistic explanation. p53 binding sequence was identified in
mtDNA suggested that p53 might be involved in the regulation of
mitochondrial transcription and replication (Heyne et al, 2004). In
addition, p53 might also enhance the DNA replication function of
mtDNA polymerase g through their interaction. So, the loss of p53
owing to the mutations in the type II tumours could result in the
decrease of mtDNA replication (Achanta et al, 2005).
Taken together, the finding of grade and histological associated
change in mtDNA copy number provide a novel insight of the role
of mtDNA alterations in cancer progression. Mitochondrial DNA
content in cell may be potentially used as a tool to predict
prognosis. Mechanisms of mtDNA maintenance in carcinoma cells
warrant further investigation.
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